SynthesisDermatology and therapy2026
Comorbidities in Discoid Lupus: A Systematic Review and Meta-analysis of Prevalence and Association.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDiscoid lupus erythematosus (DLE) is a chronic inflammatory scarring alopecia that may be accompanied by a broad range of systemic and extracutaneous comorbidities. However, the prevalence and magnitude of these associations have not been comprehensively quantified. Our objective was to systematically evaluate the prevalence and associated risk of comorbidities in patients with discoid lupus erythematosus.
methodsWe conducted a systematic review and random-effects meta-analysis in accordance with PRISMA 2020 guidelines, prospectively registered in PROSPERO (CRD420250656067). MEDLINE and Embase were searched from inception to June 2025. Observational studies reporting comorbidities in patients with DLE were included. Pooled prevalence estimates and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Between-study heterogeneity was assessed using the I
resultsIn total, 25 studies were included. Pooled prevalence estimates indicated a high frequency of systemic lupus erythematosus (SLE) (22.0%), hypertension (24.3%), depression (38.8%), and hypothyroidism (12.4%) among patients with DLE. Sensitivity analyses showed stable prevalence estimates for SLE and hypertension, with moderate variability for hypothyroidism and depression. Meta-analyses of case-control studies demonstrated significant associations between DLE and cardiovascular disease (OR 3.85, 95% CI 1.67-8.88), hypothyroidism (OR 2.55, 95% CI 1.79-3.61), hypertension (OR 2.22, 95% CI 1.91-2.58), depression (OR 2.21, 95% CI 1.71-2.85), and anxiety (OR 2.40, 95% CI 1.40-4.11). Associations with type 2 diabetes were more modest, while smoking was not significantly associated. Most association analyses were based on a limited number of studies.
conclusionsPatients with discoid lupus erythematosus exhibit a substantial burden of systemic, cardiometabolic, endocrine, and psychiatric comorbidities. While prevalence estimates were generally consistent, associations should be interpreted cautiously owing to limited available evidence. These findings highlight the importance of comprehensive clinical assessment and multidisciplinary management of patients with DLE.
trial registrationThe study protocol was prospectively registered in PROSPERO (CRD420250656067).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.